Familial Mediterranean fever

Gattorno M, Hofer M, Federici S, et al. Classification criteria for autoinflammatory recurrent fevers. Ann Rheum Dis. 2019 Aug;78(8):1025-32.Full text  Abstract

Giancane G, Ter Haar NM, Wulffraat N, et al. Evidence-based recommendations for genetic diagnosis of familial Mediterranean fever. Ann Rheum Dis. 2015 Apr;74(4):635-41. Abstract

Ozen S, Demirkaya E, Erer B, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis. 2016 Apr;75(4):644-51. Abstract

Kallinich T, Haffner D, Niehues T, et al. Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement. Pediatrics. 2007 Feb;119(2):e474-83. Abstract

Hentgen V, Grateau G, Kone-Paut I, et al. Evidence-based recommendations for the practical management of familial Mediterranean fever. Semin Arthritis Rheum. 2013 Dec;43(3):387-91. Abstract

1. Siegal S. Benign paroxysmal peritonitis. Gastroenterology. 1949 Feb;12(2):234-47. Abstract

2. Grateau G. Clinical and genetic aspects of the hereditary periodic fever syndromes. Rheumatology (Oxford). 2004 Apr;43(4):410-5.Full text  Abstract

3. Zaks N, Shinar Y, Padeh S, et al. Analysis of the three most common MEFV mutations in 412 patients with familial Mediterranean fever. Isr Med Assoc J. 2003 Aug;5(8):585-8.Full text  Abstract

4. Tunca M, Akar S, Onen F, et al; Turkish FMF Study Group. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore). 2005 Jan;84(1):1-11. Abstract

5. Gattorno M, Hofer M, Federici S, et al. Classification criteria for autoinflammatory recurrent fevers. Ann Rheum Dis. 2019 Aug;78(8):1025-32.Full text  Abstract

6. Sohar E, Gafni J, Pras M, et al. Familial Mediterranean fever: a survey of 470 cases and review of the literature. Am J Med. 1967 Aug;43(2):227-53. Abstract

7. Saatci U, Ozen S, Ozdemir S, et al. Familial Mediterranean fever in children: report of a large series and discussion of the risk and prognostic factors of amyloidosis. Eur J Pediatr. 1997 Aug;156(8):619-23. Abstract

8. Blum A, Gafni J, Sohar E, et al. Amyloidosis as the sole manifestation of familial Mediterranean fever (FMF): further evidence of its genetic nature. Ann Intern Med. 1962 Nov;57:795-9. Abstract

9. Balci B, Tinaztepe K, Yilmaz E, et al. MEFV gene mutations in familial Mediterranean fever phenotype II patients with renal amyloidosis in childhood: a retrospective clinicopathological and molecular study. Nephrol Dial Transplant. 2002 Nov;17(11):1921-3.Full text  Abstract

10. Melikoğlu M, Ozdoğan H, Korkmaz C, et al. A survey of phenotype II in familial Mediterranean fever. Ann Rheum Dis. 2000 Nov;59(11):910-3.Full text  Abstract

11. Ben-Chetrit E, Levy M. Familial Mediterranean fever. Lancet. 1998 Feb 28;351(9103):659-64. Abstract

12. Özen S. Update on the epidemiology and disease outcome of familial Mediterranean fever. Best Pract Res Clin Rheumatol. 2018 Apr;32(2):254-60. Abstract

13. Tufan A, Lachmann HJ. Familial Mediterranean fever, from pathogenesis to treatment: a contemporary review. Turk J Med Sci. 2020 Nov 3;50(si-2):1591-610.Full text  Abstract

14. Tunca M, Ozdogan H. Molecular and genetic characteristics of hereditary autoinflammatory diseases. Curr Drug Targets Inflamm Allergy. 2005 Feb;4(1):77-80. Abstract

15. Tchernitchko D, Moutereau S, Legendre M, et al. MEFV analysis is of particularly weak diagnostic value for recurrent fevers in Western European Caucasian patients. Arthritis Rheum. 2005 Nov;52(11):3603-5.Full text  Abstract

16. Majeed HA, Rawashdeh M, el-Shanti H, et al. Familial Mediterranean fever in children: the expanded clinical profile. QJM. 1999 Jun;92(6):309-18.Full text  Abstract

17. Gershoni-Baruch R, Brik R, Lidar M, et al. Male sex coupled with articular manifestations cause a 4-fold increase in susceptibility to amyloidosis in patients with familial Mediterranean fever homozygous for the M694V-MEFV mutation. J Rheumatol. 2003 Feb;30(2):308-12. Abstract

18. The International FMF Consortium. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell. 1997 Aug 22;90(4):797-807. Abstract

19. French FMF Consortium. A candidate gene for familial Mediterranean fever. Nat Genet. 1997 Sep;17(1):25-31. Abstract

20. Gershoni-Baruch R, Shinawi M, Leah K, et al. Familial Mediterranean fever: prevalence, penetrance and genetic drift. Eur J Hum Genet. 2001 Aug;9(8):634-7.Full text  Abstract

21. Brik R, Litmanovich D, Berkowitz D, et al. Incidence of familial Mediterranean fever (FMF) mutations among children of Mediterranean extraction with functional abdominal pain. J Pediatr. 2001 May;138(5):759-62. Abstract

22. Gershoni-Baruch R, Brik R, Shinawi M, et al. The differential contribution of MEFV mutant alleles to the clinical profile of familial Mediterranean fever. Eur J Hum Genet. 2002 Feb;10(2):145-9.Full text  Abstract

23. Aganna E, Hawkins PN, Ozen S, et al. Allelic variants in genes associated with hereditary periodic fever syndromes as susceptibility factors for reactive systemic AA amyloidosis. Genes Immun. 2004 Jun;5(4):289-93. Abstract

24. Akar N, Akar E, Yalçinkaya F. E148Q of the MEFV gene causes amyloidosis in familial Mediterranean fever patients. Pediatrics. 2001 Jul;108(1):215. Abstract

25. Sugiura T, Kawaguchi Y, Fujikawa S, et al. Familial Mediterranean fever in three Japanese patients, and a comparison of the frequency of MEFV gene mutations in Japanese and Mediterranean populations. Mod Rheumatol. 2008;18(1):57-9. Abstract

26. Giancane G, Ter Haar NM, Wulffraat N, et al. Evidence-based recommendations for genetic diagnosis of familial Mediterranean fever. Ann Rheum Dis. 2015 Apr;74(4):635-41. Abstract

27. Topaloglu R, Batu ED, Yıldız Ç, et al. Familial Mediterranean fever patients homozygous for E148Q variant may have milder disease. Int J Rheum Dis. 2018 Oct;21(10):1857-62. Abstract

28. Tirosh I, Yacobi Y, Vivante A, et al. Clinical significance of E148Q heterozygous variant in paediatric familial Mediterranean fever. Rheumatology (Oxford). 2021 Nov 3;60(11):5447-51. Abstract

29. Arici ZS, Romano M, Piskin D, et al. Evaluation of E148Q and concomitant AA amyloidosis in patients with familial Mediterranean fever. J Clin Med. 2021 Aug 10;10(16):3511.Full text  Abstract

30. Kastner DL. Familial Mediterranean fever: the genetics of inflammation. Hosp Pract (Minneap). 1998 Apr 15;33(4):131-4, 139-40, 143-6 passim. Abstract

31. Booth DR, Gillmore JD, Lachmann HJ, et al. The genetic basis of autosomal dominant familial Mediterranean fever. QJM. 2000 Apr;93(4):217-21.Full text  Abstract

32. Aldea A, Campistol JM, Arostegui JI, et al. A severe autosomal-dominant periodic inflammatory disorder with renal AA amyloidosis and colchicine resistance associated to the MEFV H478Y variant in a Spanish kindred: an unusual familial Mediterranean fever phenotype or another MEFV-associated periodic inflammatory disorder? Am J Med Genet A. 2004 Jan 1;124A(1):67-73.Full text  Abstract

33. Stoffels M, Szperl A, Simon A, et al. MEFV mutations affecting pyrin amino acid 577 cause autosomal dominant autoinflammatory disease. Ann Rheum Dis. 2014 Feb;73(2):455-61. Abstract

34. Kone-Paut I, Hentgen V, Guillaume-Czitrom S, et al. The clinical spectrum of 94 patients carrying a single mutated MEFV allele. Rheumatology (Oxford). 2009 Jul;48(7):840-2.Full text  Abstract

35. Marek-Yagel D, Berkun Y, Padeh S, et al. Clinical disease among patients heterozygous for familial Mediterranean fever. Arthritis Rheum. 2009 Jun;60(6):1862-6.Full text  Abstract

36. Moradian MM, Sarkisian T, Ajrapetyan H, et al. Genotype-phenotype studies in a large cohort of Armenian patients with familial Mediterranean fever suggest clinical disease with heterozygous MEFV mutations. J Hum Genet. 2010 Jun;55(6):389-93. Abstract

37. Soriano A, Manna R. Familial Mediterranean fever: new phenotypes. Autoimmun Rev. 2012 Nov;12(1):31-7. Abstract

38. Touitou I. Inheritance of autoinflammatory diseases: shifting paradigms and nomenclature. J Med Genet. 2013 Jun;50(6):349-59.Full text  Abstract

39. Federici S, Calcagno G, Finetti M, et al. Clinical impact of MEFV mutations in children with periodic fever in a prevalent western European Caucasian population. Ann Rheum Dis. 2012 Dec;71(12):1961-5. Abstract

40. Karadag O, Tufan A, Yazisiz V, et al. The factors considered as trigger for the attacks in patients with familial Mediterranean fever. Rheumatol Int. 2013 Apr;33(4):893-7. Abstract

41. Ozen S, Demirkaya E, Amaryan G, et al. Results from a multicentre international registry of familial Mediterranean fever: impact of environment on the expression of a monogenic disease in children. Ann Rheum Dis. 2014 Apr;73(4):662-7. Abstract

42. Pras E, Aksentijevich I, Gruberg L, et al. Mapping of a gene causing familial Mediterranean fever to the short arm of chromosome 16. N Engl J Med. 1992 Jun 4;326(23):1509-13.Full text  Abstract

43. Chae JJ, Wood G, Masters SL, et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci U S A. 2006 Jun 27;103(26):9982-7.Full text  Abstract

44. Papin S, Cuenin S, Agostini L, et al. The SPRY domain of Pyrin, mutated in familial Mediterranean fever patients, interacts with inflammasome components and inhibits proIL-1beta processing. Cell Death Differ. 2007 Aug;14(8):1457-66.Full text  Abstract

45. Chae JJ, Aksentijevich I, Kastner DL. Advances in the understanding of familial Mediterranean fever and possibilities for targeted therapy. Br J Haematol. 2009 Sep;146(5):467-78.Full text  Abstract

46. Simon A, van der Meer JW. Pathogenesis of familial periodic fever syndromes or hereditary autoinflammatory syndromes. Am J Physiol Regul Integr Comp Physiol. 2007 Jan;292(1):R86-98.Full text  Abstract

47. Xu H, Yang J, Gao W, et al. Innate immune sensing of bacterial modifications of Rho GTPases by the pyrin inflammasome. Nature. 2014 Sep 11;513(7517):237-41. Abstract

48. Ben-Zvi I, Danilesko I, Yahalom G, et al. Risk factors for amyloidosis and impact of kidney transplantation on the course of familial Mediterranean fever. Isr Med Assoc J. 2012 Apr;14(4):221-4.Full text  Abstract

49. Sarkisian T, Ajrapetyan H, Shahsuvaryan G. Molecular study of FMF patients in Armenia. Curr Drug Targets Inflamm Allergy. 2005 Feb;4(1):113-6. Abstract

50. Kone Paut I, Dubuc M, Sportouch J, et al. Phenotype-genotype correlation in 91 patients with familial Mediterranean fever reveals a high frequency of cutaneomucous features. Rheumatology (Oxford). 2000 Nov;39(11):1275-9. Abstract

51. Dewalle M, Domingo C, Rozenbaum M, et al. Phenotype-genotype correlation in Jewish patients suffering from familial Mediterranean fever. Eur J Hum Genet. 1998 Jan;6(1):95-7.Full text  Abstract

52. Grateau G. The relation between familial Mediterranean fever and amyloidosis. Curr Opin Rheumatol. 2000 Jan;12(1):61-4. Abstract

53. Sidi G, Shinar Y, Livneh A, et al. Protracted febrile myalgia of familial Mediterranean fever: mutation analysis and clinical correlations. Scand J Rheumatol. 2000;29(3):174-6. Abstract

54. Grateau G, Pêcheux C, Cazeneuve C, et al. Clinical versus genetic diagnosis of familial Mediterranean fever. QJM. 2000 Apr;93(4):223-9.Full text  Abstract

55. Guzel F, Romano M, Keles E, et al. Next generation sequencing based multiplex long-range PCR for routine genotyping of autoinflammatory disorders. Front Immunol. 2021 Jun 9;12:666273.Full text  Abstract

56. Ozen S, Bakkaloglu A, Yilmaz E, et al. Mutations in the gene for familial Mediterranean fever: do they predispose to inflammation? J Rheumatol. 2003 Sep;30(9):2014-8. Abstract

57. Lachmann HJ, Sengül B, Yavuzşen TU, et al. Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford). 2006 Jun;45(6):746-50.Full text  Abstract

58. Ozen S. Changing concepts in familial Mediterranean fever: is it possible to have an autosomal-recessive disease with only one mutation? Arthritis Rheum. 2009 Jun;60(6):1575-7.Full text  Abstract

59. Touitou I, Sarkisian T, Medlej-Hashim M, et al. Country as the primary risk factor for renal amyloidosis in familial Mediterranean fever. Arthritis Rheum. 2007 May;56(5):1706-12.Full text  Abstract

60. Simon A, van der Meer JW, Vesely R, et al. Approach to genetic analysis in the diagnosis of hereditary autoinflammatory syndromes. Rheumatology (Oxford). 2006 Mar;45(3):269-73.Full text  Abstract

61. Livneh A, Langevitz P, Zemer D, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum. 1997 Oct;40(10):1879-85. Abstract

62. Demirkaya E, Saglam C, Turker T, et al. Performance of different diagnostic criteria for familial Mediterranean fever in children with periodic fevers: results from a multicenter international registry. J Rheumatol. 2016 Jan;43(1):154-60. Abstract

63. Yalçinkaya F, Ozen S, Ozçakar ZB, et al. A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. Rheumatology (Oxford). 2009 Apr;48(4):395-8.Full text  Abstract

64. Padeh S, Livneh A, Pras E, et al. Familial Mediterranean fever in children presenting with attacks of fever alone. J Rheumatol. 2010 Apr;37(4):865-9. Abstract

65. Romano M, Piskin D, Berard RA, et al. Cardiovascular disease risk assessment in patients with familial Mediterranean fever related renal amyloidosis. Sci Rep. 2020 Oct 27;10(1):18374.Full text  Abstract

66. Sahin S, Romano M, Guzel F, et al. Assessment of surrogate markers for cardiovascular disease in familial Mediterranean fever-related amyloidosis patients homozygous for M694V mutation in MEFV gene. Life (Basel). 2022 Apr 25;12(5):631.Full text  Abstract

67. Berkun Y, Padeh S, Reichman B, et al. A single testing of serum amyloid a levels as a tool for diagnosis and treatment dilemmas in familial Mediterranean fever. Semin Arthritis Rheum. 2007 Dec;37(3):182-8. Abstract

68. Goldfinger SE. Colchicine for familial Mediterranean fever. N Engl J Med. 1972 Dec 21;287(25):1302. Abstract

69. Demirkaya E, Erer B, Ozen S, et al. Efficacy and safety of treatments in familial Mediterranean fever: a systematic review. Rheumatol Int. 2016 Mar;36(3):325-31. Abstract

70. Livneh A, Langevitz P. Diagnostic and treatment concerns in familial Mediterranean fever. Baillieres Best Pract Res Clin Rheumatol. 2000 Sep;14(3):477-98. Abstract

71. Brik R, Shinawi M, Kasinetz L, et al. The musculoskeletal manifestations of familial Mediterranean fever in children genetically diagnosed with the disease. Arthritis Rheum. 2001 Jun;44(6):1416-9.Full text  Abstract

72. Livneh A, Langevitz P, Zemer D, et al. The changing face of familial Mediterranean fever. Semin Arthitis Rheum. 1996 Dec;26(3):612-27. Abstract

73. Rimar D, Rosner I, Rozenbaum M, et al. Familial Mediterranean fever: an association with non-alcoholic fatty liver disease. Clin Rheumatol. 2011 Jul;30(7):987-91. Abstract

74. Tweezer-Zaks N, Doron-Libner A, Weiss P, et al. Familial Mediterranean fever and cryptogenic cirrhosis. Medicine (Baltimore). 2007 Nov;86(6):355-62. Abstract

75. Barzilai A, Langevitz P, Goldberg I, et al. Erysipelas-like erythema of familial Mediterranean fever: clinicopathologic correlation. J Am Acad Dermatol. 2000 May;42(5 Pt 1):791-5. Abstract

76. Feld O, Yahalom G, Livneh A. Neurologic and other systemic manifestations in FMF: published and own experience. Best Pract Res Clin Rheumatol. 2012 Feb;26(1):119-33. Abstract

77. Lossos A, Eliashiv S, Ben-Chetrit E, et al. Optic neuritis associated with familial Mediterranean fever. J Clin Neuroophthalmol. 1993 Jun;13(2):141-3. Abstract

78. Dabestani A, Noble LM, Child JS, et al. Pericardial disease in familial Mediterranean fever: an echocardiographic study. Chest. 1982 May;81(5):592-5. Abstract

79. Kees S, Langevitz P, Zemer D, et al. Attacks of pericarditis as a manifestation of familial Mediterranean fever (FMF). QJM. 1997 Oct;90(10):643-7. Abstract

80. Feder HM, Salazar JC. A clinical review of 105 patients with PFAPA (a periodic fever syndrome). Acta Paediatr. 2010 Feb;99(2):178-84. Abstract

81. Thomas KT, Feder HM Jr, Lawton AR, et al. Periodic fever syndrome in children. J Pediatr. 1999 Jul;135(1):15-21. Abstract

82. Gattorno M, Sormani MP, D'Osualdo A, et al. A diagnostic score for molecular analysis of hereditary autoinflammatory syndromes with periodic fever in children. Arthritis Rheum. 2008 Jun;58(6):1823-32.Full text  Abstract

83. Chitkara P, Stojanov S, Kastner DL. The hereditary autoinflammatory syndromes. Pediatr Infect Dis J. 2007 Apr;26(4):353-4. Abstract

84. Frenkel J, Kuis W. Overt and occult rheumatic diseases: the child with chronic fever. Best Pract Res Clin Rheumatol. 2002 Jul;16(3):443-69. Abstract

85. Farasat S, Aksentijevich I, Toro J. Autoinflammatory diseases: clinical and genetic advances. Arch Dermatol. 2008 Mar;144(3):392-402. Abstract

86. Masson C, Simon V, Hoppe E, et al. Tumor necrosis factor receptor-associated periodic syndrome (TRAPS): definition, semiology, prognosis, pathogenesis, treatment, and place relative to other periodic joint diseases. Joint Bone Spine. 2004 Jul;71(4):284-90. Abstract

87. Williamson LM, Hull D, Mehta R, et al. Familial Hibernian fever. Q J Med. 1982;51(204):469-80. Abstract

88. Samuels J, Ozen S. Familial Mediterranean fever and other autoinflammatory syndromes: evaluation of the patient with recurrent fever. Curr Opin Rheumatol. 2006 Jan;18(1):108-17. Abstract

89. Kastner D. Hereditary periodic fever syndromes. Hematology Am Soc Hematol Educ Program. 2005:74-81.Full text  Abstract

90. Lidar M, Scherrmann JM, Shinar Y, et al. Colchicine nonresponsiveness in familial Mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization. Semin Arthritis Rheum. 2004 Feb;33(4):273-82. Abstract

91. Livneh A, Zemer D, Langevitz P, et al. Colchicine treatment of AA amyloidosis of familial Mediterranean fever. An analysis of factors affecting outcome. Arthritis Rheum. 1994 Dec;37(12):1804-11. Abstract

92. Terkeltaub RA. Colchicine update: 2008. Semin Arthritis Rheum. 2009 Jun;38(6):411-9. Abstract

93. Majeed HA, Al-Qudah AK, Qubain H, et al. The clinical patterns of myalgia in children with familial Mediterranean fever. Semin Arthritis Rheum. 2000 Oct;30(2):138-43. Abstract

94. Meinzer U, Quartier P, Alexandra JF, et al. Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. Semin Arthritis Rheum. 2011 Oct;41(2):265-71. Abstract

95. Hashkes PJ, Spalding SJ, Giannini EH, et al. Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial. Ann Intern Med. 2012 Oct 16;157(8):533-41. Abstract

96. Ozen S, Bilginer Y, Aktay Ayaz N, et al. Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine. J Rheumatol. 2011 Mar;38(3):516-8. Abstract

97. Kuemmerle-Deschner JB, Gautam R, George AT, et al. A systematic literature review of efficacy, effectiveness and safety of biologic therapies for treatment of familial Mediterranean fever. Rheumatology (Oxford). 2020 Oct 1;59(10):2711-24.Full text  Abstract

98. Poddighe D, Romano M, Garcia-Bournissen F, et al. Conventional and novel therapeutic options in children with familial Mediterranean fever: a rare autoinflammatory disease. Br J Clin Pharmacol. 2022 Jun;88(6):2484-99. Abstract

99. Kacar M, Savic S, van der Hilst JCH. The efficacy, safety and tolerability of canakinumab in the treatment of familial mediterranean fever: a systematic review of the literature. J Inflamm Res. 2020 Mar 9;13:141-49. Abstract

100. Yin X, Tian F, Wu B, et al. Interventions for reducing inflammation in familial Mediterranean fever. Cochrane Database Syst Rev. 2022 Mar 29;(3):CD010893.Full text  Abstract

101. Ter Haar N, Lachmann H, Özen S, et al. Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis. 2013 May;72(5):678-85. Abstract

102. Hentgen V, Grateau G, Kone-Paut I, et al. Evidence-based recommendations for the practical management of familial Mediterranean fever. Semin Arthritis Rheum. 2013 Dec;43(3):387-91. Abstract

103. Bilgen SA, Kilic L, Akdogan A, et al. Effects of anti-tumor necrosis factor agents for familial Mediterranean fever patients with chronic arthritis and/or sacroiliitis who were resistant to colchicine treatment. J Clin Rheumatol. 2011 Oct;17(7):358-62. Abstract

104. Ben-Chetrit E, Aamar S. About colchicine compliance, resistance and virulence. Clin Exp Rheumatol. 2009 Mar-Apr;27(2 Suppl 53):S1-3. Abstract

105. Polat A, Acikel C, Sozeri B, et al. Comparison of the efficacy of once- and twice-daily colchicine dosage in pediatric patients with familial Mediterranean fever - a randomized controlled noninferiority trial. Arthritis Res Ther. 2016 Apr 7;18:85.Full text  Abstract

106. Ben-Chetrit E, Levy M. Colchicine prophylaxis in familial Mediterranean fever: reappraisal after 15 years. Semin Arthritis Rheum. 1991 Feb;20(4):241-6. Abstract

107. Kallinich T, Haffner D, Niehues T, et al. Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement. Pediatrics. 2007 Feb;119(2):e474-83. Abstract

108. Ozen S, Demirkaya E, Erer B, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis. 2016 Apr;75(4):644-51. Abstract

109. Sayarlioglu M, Sayarlioglu H, Ozen S, et al. Colchicine-induced myopathy in a teenager with familial Mediterranean fever. Ann Pharmacother. 2003 Dec;37(12):1821-4. Abstract

110. Colak S, Tekgoz E, Cinar M, et al. The assessment of tocilizumab therapy on recurrent attacks of patients with familial Mediterranean fever: a retrospective study of 15 patients. Mod Rheumatol. 2021 Jan;31(1):223-25. Abstract

111. Ozen S, Demirkaya E, Erer B, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis. 2016 Apr;75(4):644-51. Abstract

112. Simon A, van der Meer JW. Pathogenesis of familial periodic fever syndromes or hereditary autoinflammatory syndromes. Am J Physiol Regul Integr Comp Physiol. 2007 Jan;292(1):R86-98.Full text  Abstract

113. Kallinich T, Haffner D, Niehues T, et al. Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement. Pediatrics. 2007 Feb;119(2):e474-83. Abstract

114. Dinarello CA, Wolff SM, Goldfinger SE, et al. Colchicine therapy for familial mediterranean fever: a double-blind trial. N Engl J Med. 1974 Oct 31;291(18):934-7. Abstract

115. Ben-Chetrit E, Berkun Y, Ben-Chetrit E, et al. The outcome of pregnancy in the wives of men with familial mediterranean fever treated with colchicine. Semin Arthritis Rheum. 2004 Oct;34(2):549-52. Abstract

116. Hentgen V, Grateau G, Kone-Paut I, et al. Evidence-based recommendations for the practical management of familial Mediterranean fever. Semin Arthritis Rheum. 2013 Dec;43(3):387-91. Abstract

117. Zemer D, Pras M, Sohar E, et al. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med. 1986 Apr 17;314(16):1001-5. Abstract

118. Langevitz P, Livneh A, Zemer D, et al. Seronegative spondyloarthropathy in familial Mediterranean fever. Semin Arthritis Rheum. 1997 Oct;27(2):67-72. Abstract

119. Ben-Chetrit E, Berkun Y, Ben-Chetrit E, et al. The outcome of pregnancy in the wives of men with familial Mediterranean fever treated with colchicine. Semin Arthritis Rheum. 2004 Oct;34(2):549-52. Abstract

120. Ben-Chetrit E, Levy M. Reproductive system in familial Mediterranean fever: an overview. Ann Rheum Dis. 2003 Oct;62(10):916-9. Abstract

121. Ben-Chetrit E, Scherrmann JM, Levy M. Colchicine in breast milk of patients with familial Mediterranean fever. Arthritis Rheum. 1996 Jul;39(7):1213-7. Abstract

122. Ben-Chetrit E, Ben-Chetrit A, Berkun Y, et al. Pregnancy outcomes in women with familial Mediterranean fever receiving colchicine: is amniocentesis justified? Arthritis Care Res (Hoboken). 2010 Feb;62(2):143-8.Full text  Abstract

123. Aksu K, Keser G. Coexistence of vasculitides with familial Mediterranean fever. Rheumatol Int. 2011 Oct;31(10):1263-74. Abstract

124. Ozçakar ZB, Yalçınkaya F. Vascular comorbidities in familial Mediterranean fever. Rheumatol Int. 2011 Oct;31(10):1275-81. Abstract

125. Espinosa G, Arostegui JI, Plaza S, et al. Behçet's disease and hereditary periodic fever syndromes: casual association or causal relationship? Clin Exp Rheumatol. 2005 Jul-Aug;23(4 Suppl 38):S64-6. Abstract

126. Imirzalioglu N, Dursun A, Tastan B, et al. MEFV gene is a probable susceptibility gene for Behçet's disease. Scand J Rheumatol. 2005;34(1):56-8. Abstract

127. Schwartz T, Langevitz P, Zemer D, et al. Behçet's disease in familial Mediterranean fever: characterization of the association between the two diseases. Semin Arthritis Rheum. 2000 Apr;29(5):286-95. Abstract

128. Livneh A, Aksentijevich I, Langevitz P, et al. A single mutated MEFV allele in Israeli patients suffering from familial Mediterranean fever and Behçet's disease (FMF-BD). Eur J Hum Genet. 2001 Mar;9(3):191-6.Full text  Abstract

129. Korkmaz C, Kaşifoğlu T. Changes in the liver function tests during the attacks of familial Mediterranean fever. Rheumatol Int. 2007 Feb;27(4):395-8. Abstract

130. Erer B, Demirkaya E, Ozen S, et al. What is the best acute phase reactant for familial Mediterranean fever follow-up and its role in the prediction of complications? A systematic review. Rheumatol Int. 2016 Apr;36(4):483-7. Abstract

131. Terkeltaub RA, Furst DE, Digiacinto JL, et al. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum. 2011 Aug;63(8):2226-37.Full text  Abstract

132. Finkelstein Y, Aks SE, Hutson JR, et al. Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol (Phila). 2010 Jun;48(5):407-14. Abstract

133. Piskin D, Arici ZS, Konukbay D, et al. Number of episodes can be used as a disease activity measure in familial Mediterranean fever. Front Pediatr. 2022 Apr 27;10:822473.Full text  Abstract

134. Demirkaya E, Acikel C, Hashkes P, et al. Development and initial validation of international severity scoring system for familial Mediterranean fever (ISSF). Ann Rheum Dis. 2016 Jun;75(6):1051-6. Abstract